Prix Venus Medtech (Hangzhou) Inc. (02500.HK)

Venus Medtech (Hangzhou), Inc. provides transcatheter heart valve medical device. The company is headquartered in Hangzhou, Zhejiang and currently employs 605 full-time employees. The company went IPO on 2019-12-10. The firm mainly engages in minimally invasive medical devices and auxiliary instruments and equipment for the treatment of heart valve diseases. The firm provides interventional heart valve devices for valvular heart disease including aortic valve, pulmonic valve, mitral valve and tricuspid valve, a radio frequency ablation system for interventional treatment of HCM, a renal artery denervation ultrasound ablation system for interventional treatment of hypertension and other accessory consumables. The firm's main products include the VenusA-Valve System, VenusA-Plus System, VenusA-Pilot System, VenusP-Valve System, TMVR valve, TTVR valve, valvuloplasty balloons V8/TAV8 and TriGUARD3 Cerebral Embolic Protection Device. The firm mainly conducts its businesses in the domestic market and overseas markets.